Meta Biomed Co., Ltd. announces an Equity Buyback for KRW 500 million worth of its shares.
October 29, 2018 at 12:57 am
Share
Meta Biomed Co., Ltd. (KOSDAQ:A059210) announces a share repurchase program. Under the program, the company will repurchase shares up to KRW 500 million worth of its shares under the contract with KB Securities Co., Ltd. The purpose of the program is to improve shareholder value and stabilize stock price. The program will be valid until October 28, 2019. As of October 28, 2018, the company had 370,000 shares in treasury under the dividend capacity and no shares in treasury under other buyback.
Meta Biomed Co., Ltd. is a Korea-based company engaged in the manufacture of medical materials and equipment for biotechnology and dental areas. The Company mainly operates its business through three divisions: suture material division, dental division and bone material division. Its suture material division provides suture materials, such as polyglycolic acid (PGA) synthetic absorbable braids, polyglycolic acid-co-lactic acid (PGLA) absorbable braids, polydioxanone (PDO) synthetic absorbable monofilaments, polyglycolide-co-epsilon-caprolactone (PGCL) synthetic absorbable monofilaments and others. Its dental division provides dental materials and equipment, such as gutta percha cordless obturation systems, electronic apex locators, taper points, root canal sealers, root canal filling materials and others. Its bone materials division provides bone graft substitutes. It also distributes dental-related products.
META BIOMED CO., LTD. 
